Greenwich Lifesciences Inc
NASDAQ:GLSI
Income Statement
Earnings Waterfall
Greenwich Lifesciences Inc
Income Statement
Greenwich Lifesciences Inc
| Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||
| Operating Expenses |
(5)
|
(3)
|
(4)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(5)
|
(6)
|
(6)
|
(8)
|
(8)
|
(8)
|
(9)
|
(9)
|
(9)
|
(10)
|
(11)
|
(11)
|
(16)
|
(17)
|
(18)
|
(20)
|
|
| Selling, General & Administrative |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(4)
|
(4)
|
|
| Research & Development |
(4)
|
(3)
|
(3)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(9)
|
(9)
|
(13)
|
(13)
|
(15)
|
(16)
|
|
| Operating Income |
(5)
N/A
|
(3)
+26%
|
(4)
-3%
|
(1)
+68%
|
(1)
+7%
|
(2)
-77%
|
(2)
-19%
|
(3)
-24%
|
(3)
-22%
|
(5)
-36%
|
(6)
-30%
|
(6)
0%
|
(8)
-25%
|
(8)
-7%
|
(8)
-3%
|
(9)
-12%
|
(9)
-1%
|
(9)
+1%
|
(10)
-3%
|
(11)
-9%
|
(11)
-2%
|
(16)
-49%
|
(17)
-5%
|
(18)
-8%
|
(20)
-8%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(5)
N/A
|
(3)
+26%
|
(4)
-3%
|
(1)
+68%
|
(1)
+7%
|
(2)
-77%
|
(2)
-19%
|
(3)
-24%
|
(3)
-22%
|
(5)
-36%
|
(6)
-30%
|
(6)
N/A
|
(7)
-25%
|
(8)
-6%
|
(8)
-2%
|
(9)
-11%
|
(9)
-1%
|
(9)
+0%
|
(9)
-4%
|
(10)
-11%
|
(10)
-3%
|
(16)
-50%
|
(17)
-5%
|
(18)
-9%
|
(19)
-8%
|
|
| Net Income | ||||||||||||||||||||||||||
| Income from Continuing Operations |
(5)
|
(3)
|
(4)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(5)
|
(6)
|
(6)
|
(7)
|
(8)
|
(8)
|
(9)
|
(9)
|
(9)
|
(9)
|
(10)
|
(10)
|
(16)
|
(17)
|
(18)
|
(19)
|
|
| Net Income (Common) |
(5)
N/A
|
(3)
+26%
|
(4)
-3%
|
(1)
+68%
|
(1)
+7%
|
(2)
-77%
|
(2)
-19%
|
(3)
-24%
|
(3)
-22%
|
(5)
-36%
|
(6)
-30%
|
(6)
N/A
|
(7)
-25%
|
(8)
-6%
|
(8)
-2%
|
(9)
-11%
|
(9)
-1%
|
(9)
+0%
|
(9)
-4%
|
(10)
-11%
|
(10)
-3%
|
(16)
-50%
|
(17)
-5%
|
(18)
-9%
|
(19)
-8%
|
|
| EPS (Diluted) |
-0.39
N/A
|
-0.29
+26%
|
-0.3
-3%
|
-0.1
+67%
|
-0.09
+10%
|
-0.15
-67%
|
-0.17
-13%
|
-0.21
-24%
|
-0.26
-24%
|
-0.35
-35%
|
-0.46
-31%
|
-0.46
N/A
|
-0.57
-24%
|
-0.61
-7%
|
-0.63
-3%
|
-0.7
-11%
|
-0.71
-1%
|
-0.69
+3%
|
-0.73
-6%
|
-0.8
-10%
|
-0.81
-1%
|
-1.21
-49%
|
-1.26
-4%
|
-1.36
-8%
|
-1.42
-4%
|
|